

The Swiss biotech company Memo Therapeutics AG closes a series A financing round of 2.3 million Swiss Francs to develop and validate its MemoMAB™ antibody discovery platform

Series A financing round

July 22, 2015 - Memo Therapeutics AG today announced the successful completion of its series A financing round of 2.3 million Swiss Francs which has been raised from Swiss investors (including EVA Basel, Redalpine Venture Partners and Zürcher Kantonalbank). The funds will be used to develop and validate its MemoMAB™ antibody discovery platform. MemoMAB™ will be used for discovery of novel human-derived antibodies and of antibodies against difficult targets from animals.

About Memo Therapeutics AG

Memo Therapeutics is an innovator in the area of recombinant immunoglobulins and human-derived monoclonal antibodies. The technological core of Memo Therapeutics is MemoMAB™ – a technology enabling cost and time-effective molecular cloning and expression of the complete antibody repertoire of one or several human subjects.

Memo Therapeutics capitalizes on the MemoMAB™ platform by developing proprietary technologies and products and by offering services in the area of recombinant immunoglobulins and monoclonal antibodies.